Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market .. DelveInsight ...Middle East

The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes its use as a first-line treatment in combination with platinum-based chemotherapy, as well as a...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market .. DelveInsight )

Also on site :

• Kristen Doute Makes Bold Statement About Brittany Cartwright's Heated Reaction to Nia Sanchez
• Germany could reintroduce military draft – defense minister
• Trump predicts ‘good news’ from Russia-Ukraine talks